Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI scans may help prevent intestinal damage in Crohn's disease

NCT ID NCT04973423

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether adding regular MRI scans to standard monitoring (stool tests and symptom checks) can improve outcomes for people with Crohn's disease who are starting biotherapy. Crohn's is a chronic inflammatory bowel disease that can damage the full thickness of the intestinal wall, often leading to surgery. The study compares two groups: one receiving standard tight control with stool tests, and another also getting two additional MRI scans. The goal is to see if the MRI group spends more time in symptom-free remission without steroids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI scans added to standard monitoring
What this could lead to
If successful, adding MRI scans to standard monitoring could help prevent intestinal damage and reduce the need for surgery in Crohn's disease.
What could go wrong
This is a relatively small, early-stage trial, and the added benefit of MRI over standard monitoring may be modest. MRI is also more costly and less accessible than stool tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult Crohn's disease (age ≥ 18 years) * Symptomatic with Crohn's disease activity index (CDAI)\> 150 * Presence of objective signs of inflammatory activity (fecal calprotectin\> 250 AND sign of MRI activity) * Requiring treatment with biotherapy according to the investigator * Able to give informed consent to participate in research * Affiliation to a Social Security scheme. Exclusion Criteria: * Severe obstructive symptoms * Uncontrolled intra-abdominal abscess * Isolated anoperineal lesions * Prevention of postoperative endoscopic recurrence * Temporary or definitive ostomy * Total colectomy * Contraindication to MRI * Pregnant or breastfeeding women * Protected adults (curatorship, guardianship, saving justice) * Refusal of participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Calprotectin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Calprotectin Crohn disease MRI

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amiens university hospital

    NOT_YET_RECRUITING

    Amiens, France

  • Aurillac Hospital

    NOT_YET_RECRUITING

    Aurillac, France

  • Bayonne hospital

    NOT_YET_RECRUITING

    Bayonne, France

  • Bordeaux university hospital

    NOT_YET_RECRUITING

    Bordeaux, France

  • Chambery Hospital

    NOT_YET_RECRUITING

    Chambéry, France

  • Clermont-Ferrand University hospital

    RECRUITING

    Clermont-Ferrand, France

  • Grenoble University Hospital

    NOT_YET_RECRUITING

    Grenoble, France

  • Issoire Hospital

    NOT_YET_RECRUITING

    Issoire, France

  • LILLE university hospital

    NOT_YET_RECRUITING

    Lille, France

  • Lyon Hospital, Hospices civils de Lyon

    NOT_YET_RECRUITING

    Lyon, France

  • Montluçon Hospital

    NOT_YET_RECRUITING

    Montluçon, France

  • Montpellier University hospital

    NOT_YET_RECRUITING

    Montpellier, France

  • Nancy University hospital

    NOT_YET_RECRUITING

    Nancy, France

  • Nice University hospital

    NOT_YET_RECRUITING

    Nice, France

  • Rennes University Hospital

    NOT_YET_RECRUITING

    Rennes, France

  • Saint Etienne University Hospital

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • Thiers Hospital

    NOT_YET_RECRUITING

    Thiers, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.